FDA prioritizes Alzheimer’s therapy device

Posted on: Monday, May 13th, 2019

I reported previously (see here) on the NeuroAD cranial device from Israel’s Neuronix. It already has European approval and is now being urgently reviewed in the FDA’s Expedited Access Pathway program for breakthrough devices that target vital unmet needs.